港股異動丨微創機器人-B(2252.HK)漲超8%創新高 市值重上500億港元
格隆匯11月9日丨次新股微創機器人-B(2252.HK)大幅拉昇漲超8%,盤中高見52.9港元創上市以來新高價,總市值首次站上500億港元。公司由微創醫療分拆而來,也是港股第一家手術機器人公司。致力於設計、開發及商業化手術機器人,以協助外科醫生完成複雜的外科手術。此次IPO定價43.2港元,目前漲幅已超20%。公司淨籌14.574億港元,當中35%分配至集團的核心產品,即圖邁;21%將分配至集團的骨科手術機器人。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.